Key Points
Promising therapies for mental illnesses could see their regulatory reviews quickened.
AtaiBeckley is a potential leader in psychedelic treatments.
Shares of AtaiBeckley (NASDAQ: ATAI) leaped on Monday after President Donald Trump directed U.S. health regulators to accelerate reviews of psychedelic treatments for severe mental illnesses.
By the close of trading, AtaiBeckley's stock price was up more than 21%.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
A new class of drugs could be helping people by this summer
Trump's executive order seeks to reduce regulatory evaluation timelines for certain psychedelic compounds. Those that have received breakthrough-therapy designations from the U.S. Food and Drug Administration (FDA) could see their reviews completed in as few as one to two months.
Investors in developers of psychedelic drugs cheered the news. Industry leaders say Trump's order validates psychedelic research and will help to bring promising new drugs to patients faster.
AtaiBeckley is set to be a leader in psychedelics
With a market cap of roughly $1.8 billion, AtaiBeckley is one of the biggest psychedelic drugmakers. The mental health-focused biotechnology company is developing a nasal spray for treatment-resistant depression.
The investigational drug, BPL-003, holds breakthrough therapy designation and showed promising results in a Phase 2 study. AtaiBeckley expects to begin Phase 3 trials later this year.
With its focus on rapid-acting psychedelic treatments, AtaiBeckley could help to usher in a new wave of mental health therapies.
Should you buy stock in AtaiBeckley right now?
Before you buy stock in AtaiBeckley, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AtaiBeckley wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $524,786!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,236,406!*
Now, it’s worth noting Stock Advisor’s total average return is 994% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 20, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
